Natural Alternatives International, Inc. provided sales guidance for the second half and full year of fiscal 2020. For the second half of fiscal 2020, as compared to the same period in the prior year, the company expects sales levels to largest contract manufacturing customer to decline 20% to 25% and CarnoSyn® beta-alanine revenue to be comparable to the prior year. As a result, on an annualized basis, the company now expects consolidated fiscal 2020 revenue to decline approximately 10% to 15% as compared to the prior fiscal year.